Nanobiotix (NASDAQ:NBTX) Hits New 52-Week High - Here's What Happened

Key Points

• Nanobiotix shares reached a new 52-week high of $30.35, closing at $30.31, a significant increase from the previous close of $23.60.
• Recent analyst ratings show a mixed outlook: while HC Wainwright maintains a "buy" rating, Weiss Ratings suggest a "sell (d-)" rating, leading to a consensus rating of "Hold" with a target price of $11.00.
• Nanobiotix is focused on developing cancer treatment therapies, with its lead product candidate, NBTXR3, targeting various cancers including soft tissue sarcoma and non-small cell lung cancer.

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report)'s share price reached a new 52-week high during trading on Tuesday . The stock traded as high as $30.35 and last traded at $30.31, with a volume of 175540 shares changing hands. The stock had previously closed at $23.60.

Analyst Upgrades and Downgrades

NBTX has been the subject of several research analyst reports. HC Wainwright reiterated a "buy" rating on shares of Nanobiotix in a research note on Friday, September 19th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Nanobiotix in a research note on Wednesday, October 8th. Finally, Leerink Partners set a $14.00 target price on Nanobiotix in a research note on Thursday, September 18th. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $11.00.

Nanobiotix Stock Performance

The company has a 50 day moving average of $12.56 and a 200-day moving average of $7.21.

About Nanobiotix

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.